Susquehanna Fundamental Investments LLC Makes New $6.20 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)

Susquehanna Fundamental Investments LLC bought a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 131,799 shares of the biopharmaceutical company's stock, valued at approximately $6,200,000. Susquehanna Fundamental Investments LLC owned about 0.11% of Cytokinetics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of CYTK. Jones Financial Companies Lllp grew its stake in shares of Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Cytokinetics during the fourth quarter valued at $29,000. AlphaQuest LLC raised its holdings in shares of Cytokinetics by 113,500.0% in the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp raised its stake in Cytokinetics by 62.1% in the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 671 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of Cytokinetics by 85.8% in the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 842 shares in the last quarter.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $40.43 on Monday. Cytokinetics, Incorporated has a fifty-two week low of $32.74 and a fifty-two week high of $68.44. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The stock's fifty day moving average is $42.09 and its two-hundred day moving average is $47.11. The firm has a market capitalization of $4.82 billion, a P/E ratio of -7.51 and a beta of 0.94.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million for the quarter, compared to analysts' expectations of $14.26 million. On average, research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

CYTK has been the subject of a number of analyst reports. Stifel Nicolaus initiated coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $120.00 target price on shares of Cytokinetics in a report on Monday, April 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $72.00 price target on shares of Cytokinetics in a report on Tuesday, April 8th. Morgan Stanley set a $67.00 price objective on Cytokinetics in a research report on Friday, March 7th. Finally, JMP Securities restated a "market outperform" rating and set a $78.00 target price on shares of Cytokinetics in a research report on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Cytokinetics currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.13.

Insider Transactions at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 2,000 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $48.06, for a total transaction of $96,120.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares of the company's stock, valued at $5,578,372.26. The trade was a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert I. Blum sold 16,970 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the completion of the sale, the chief executive officer now directly owns 364,181 shares in the company, valued at approximately $15,820,022.64. This trade represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 88,360 shares of company stock worth $3,643,645. 3.40% of the stock is currently owned by insiders.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.